References
- Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
- Friberg L, Rosenqvist M, Lindgren A, et al. High prevalence of atrial fibrillation among patients with ischemic stroke. Stroke 2014;45:2599-605
- Gattellari M, Goumas C, Aitken R, et al. Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM Study (a program of research informing stroke management). Cerebrovasc Dis 2011;32:370-82
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
- Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a “real world” nationwide cohort study. Thromb Haemost 2011;106:739-49
- Frykman V, Beerman B, Ryden L, et al.; Medical Products Agency; Swedish Society of Cardiology. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-9
- Freedman SB, Gersh BJ, Lip GYH. Misperception of aspirin efficacy and safety may perpetuate anticoagulant underutilisation in atrial fibrillation. Eur Heart J 2015;36:653-6
- Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. Arch Intern Med 2012;172:1687-9
- Bushnell CD, Olson DM, Zhao X, et al. Secondary preventive medication persistence and adherence 1 year after stroke. Neurology 2011;77:1182-90
- Simons LA, Ortiz M, Germanos P, et al. Persistence on warfarin in patients with atrial fibrillation: experience in Australia 2006–2009. Aust Fam Physic 2013;42:659-61
- Schulman S, Shortt B, Robinson M, et al. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost 2013;11:1295-9
- Savelieva I, Camm AJ. Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation. Clin Cardiol 2014;37:32-47
- Sauer R, Sauer E-M, Bobinger T, et al. Adherence to oral anticoagulation in secondary stroke prevention – the first year of direct oral anticoagulants. J Stroke Cerebrovasc Dis 2015;24:78-82
- Martinez C, Katholing A, Wallenhorst C, et al. Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study. Thromb Haemost 2015;115:31-9
- Camm AJ, Pinto FJ, Hankey GJ, et al. Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace 2015;17:1007-17
- Salazar CA, del Aguila D, Cordova EG. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev 2014;3:CD009893
- Kneeland PP, Fang MC. Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence 2010;4:51-60
- Gattellari M, Worthington J, Zwar N, et al. Barriers to the use of anticoagulation for nonvalvular atrial fibrillation. A representative survey of Australian family physicians. Stroke 2008;39:227-30
- Arbit B, Hsu JC. Non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation and associated intracranial haemorrhage: a focussed review. Clin Cardiol 2015;38:684-91
- Chang H-Y, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 2015;350:h1585
- Tamayo S, Peacock WF, Patel M, et al. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27467 patients taking rivaroxaban. Clin Cardiol 2014;38:63-8
- Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51
- Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic disease. Am J Manag Care 2009;15:e22-3
- Coleman CI, Roberts MS, Sobieraj DM, et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence Curr Med Res Opin 2012;228:669-80
- Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:514-23